BioSpace News Archive

Geron Corporation announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.

Aerie Pharmaceuticals, Inc. announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. Eastern Time.

The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. CEPI will provide up to $9.25m in funding.

ValGenesis, Inc., a market leader in enterprise Validation Lifecycle Management Systems, reported exceptional company growth, achieving 68% year-over-year revenue growth and 42% growth in new customers for the financial year ending February 28, 2022.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in combination with a wide range of anticancer therapies in the treatment of numerous cancer types at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.

FSD Pharma Inc. announced today the following corporate updates.

Revelation Biosciences Inc. today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time.

Progenity, Inc. today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting.

AffyImmune Therapeutics, Inc. announced today that it will present an abstract in a poster session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Propanc Biopharma, Inc. announced that its Chief Executive Officer, Mr. James Nathanielsz, expressed concern over disruption to cancer care during the global pandemic, where patients are experiencing delays to diagnoses and treatment, to halting clinical trials.